PHARMACOGENOMICS IN RARE HEREDITARY DISORDERS: EMERGING STRATEGIES FOR PRECISION AND PERSONALISED THERAPEUTICS

Abstract

Pharmacogenomics is driving a transformative shift in the management of rare hereditary disorders, transitioning clinical care from trial-and-error prescribing to mechanism-based precision dosing. This manuscript explores the integration of high-throughput genomic sequencing, pharmacokinetic modeling, and multi-omic data to navigate the extreme clinical heterogeneity inherent in orphan diseases. We highlight the utility of predictive computational frameworks and artificial intelligence in classifying rare pathogenic variants and identifying actionable therapeutic targets. The deployment of innovative modalities, including structure-based small molecule inhibitors, CRISPR-Cas9 gene editing, and mRNA therapeutics, offers unprecedented potential to restore metabolic function and correct enzymatic deficiencies. Furthermore, patient-derived organoid models and decentralized clinical trials utilizing digital biomarkers are establishing robust ex vivo validation and real-time pharmacodynamic tracking.  Despite these clinical and technological advancements, significant systemic barriers impede routine clinical implementation. Key challenges include the interpretation of variants of uncertain significance, systemic data fragmentation, the high cost of specialized infrastructure, and rigid regulatory frameworks that struggle to accommodate iterative, individualized interventions. To overcome these hurdles, we advocate for the establishment of global, decentralized data-sharing consortia utilizing federated learning, alongside the implementation of adaptive licensing and value-based reimbursement models. Ultimately, synthesizing multidimensional omics data with longitudinal real-world evidence will democratize access to personalized therapies, establishing a sustainable blueprint for integrating precision pharmacogenomics into standard clinical care for rare disease populations.